{u'keywords': [u'hydrogel tablet technology', u'method patent', u'venlafaxine hydrochloride', u'single daily dosing', u'daily dosing formulation', u'invention', u'blood plasma', u'specification', u'Alphapharm', u'Wyeth', u'extended release', u'peak blood plasma', u'blood plasma concentration', u'prima facie', u'prima facie case', u'therapeutic blood plasma', u'extended release formulation', u'Dr Marshall', u'Professor Charman', u'interlocutory relief', u'blood plasma level', u'release formulations', u'extended release formulations', u'claims', u'Sigma decision', u'fair basis', u'Pty', u'evidence', u'venlafaxine hydrochloride formulation', u'Atlantis Corporation', u'Patents Act', u'extended release drug', u'claim', u'consistory style statements', u'venlafaxine hydrochloride tablets', u'single daily dose', u'Pty Limited', u'Wyeth Australia Pty', u'infringement', u'embodiment', u'hydrogel technology', u'venlafaxine hydrochloride laboratory', u'dissolution rate', u'blood plasma levels', u'Atlantis Corporation Pty', u'priority date', u'allegedly infringing Wyeth', u'Australia Pty Limited'], u'casename': u'Alphapharm Pty Limited v Wyeth [2009] FCA 945 (25 August 2009)', u'filename': u'training_data/09_945.xml'}